LITTLE KNOWN FACTS ABOUT OBATOCLAX MESYLATE.

Rydapt has been revealed to enhance survival in people with AML related to an FLT3 mutation. A single principal research, involving 717 this kind of individuals, compared Rydapt with placebo (a dummy treatment) originally as an addition to other cancer medicines, accompanied by cure with Rydapt or placebo alone in those whose disease responded. Abo